Foster Victor Wealth Advisors LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 102.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,719 shares of the biopharmaceutical company’s stock after buying an additional 19,626 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Pfizer were worth $1,387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter valued at $34,000. IMA Wealth Inc. raised its holdings in Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 477 shares during the period. Financial Gravity Wealth Inc. raised its holdings in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the period. Vestor Capital LLC raised its holdings in Pfizer by 60.1% in the 2nd quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 581 shares during the period. Finally, HMS Capital Management LLC bought a new position in Pfizer in the 2nd quarter worth $71,000. 71.69% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on PFE shares. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Goldman Sachs Group reaffirmed a “buy” rating and issued a $49.00 target price on shares of Pfizer in a report on Monday, June 17th. UBS Group reaffirmed a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price on the stock in a report on Tuesday, October 1st. Twelve research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $45.20.
PFE stock traded up $0.44 during trading on Friday, reaching $36.23. The company’s stock had a trading volume of 1,197,933 shares, compared to its average volume of 19,407,336. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $195.97 billion, a P/E ratio of 12.04, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66. The company’s fifty day moving average is $35.94 and its 200-day moving average is $39.97.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.77 EPS. Pfizer’s revenue for the quarter was down 1.5% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.81 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.97%. Pfizer’s payout ratio is presently 48.00%.
In other news, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Put Option Volume
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.